3,4-dihydroxyphenylacetic acid has been researched along with Parkinson Disease, Secondary in 112 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral treatment with chrysin (10 mg/kg, 28 days), culminated with the prevention of these alterations occasioned by 6-OHDA." | 5.48 | Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins. ( Antunes, MS; Boeira, SP; Goes, ATR; Jesse, CR; Lobo Ladd, AAB; Lobo Ladd, FV; Luchese, C; Paroul, N, 2018) |
| " N-Methyl(R)salsolinol induced DNA damage to human neuroblastoma SH-SY5Y cells, which could be prevented by anti-oxidants and cycloheximide." | 3.70 | Oxidation of N-methyl(R)salsolinol: involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines. ( Dostert, P; Kasamatsu, T; Maruyama, W; Naoi, M, 1998) |
| "We investigated the effect of GM1 gangliosides on a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of Parkinson disease." | 3.68 | GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice. ( Albert, ML; Davoudi, H; Durso, R; Fazzini, E; Szabo, GK, 1990) |
| "Hesperidin is a flavonoid glycoside that is frequently found in citrus fruits." | 1.62 | Hesperidin protects against behavioral alterations and loss of dopaminergic neurons in 6-OHDA-lesioned mice: the role of mitochondrial dysfunction and apoptosis. ( Antunes, MS; Boeira, SP; Cattelan Souza, L; Ladd, AABL; Ladd, FVL; Moreira, AL, 2021) |
| "Oral treatment with chrysin (10 mg/kg, 28 days), culminated with the prevention of these alterations occasioned by 6-OHDA." | 1.48 | Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins. ( Antunes, MS; Boeira, SP; Goes, ATR; Jesse, CR; Lobo Ladd, AAB; Lobo Ladd, FV; Luchese, C; Paroul, N, 2018) |
| "Reactive gliosis occurred only in response to combined PQ + MB in dorsal-medial but not ventral striatum." | 1.31 | The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. ( Baggs, RB; Cory-Slechta, DA; Richfield, EK; Tank, AW; Thiruchelvam, M, 2000) |
| " A similar dose-response relationship was determined for nifedipine, an L-type calcium channel antagonist." | 1.31 | Pharmacological involvement of the calcium channel blocker flunarizine in dopamine transmission at the striatum. ( Armando, I; Belforte, JE; Buño, W; Magariños-Azcone, C; Pazo, JH, 2001) |
| " We show in this study that repin is highly toxic to C57BL/6J mice and Sprague-Dawley rats and acutely induces uncoordinated locomotion associated with postural tremors, hypothermia, and inability to respond to sonic and tactile stimuli." | 1.30 | Repin-induced neurotoxicity in rodents. ( Choi, BH; Han, B; Kim, RC; Robles, M; Santa Cruz, K, 1998) |
| "Levodopa treatment in Parkinson's disease has been suggested to contribute to disease progression through free radical generation." | 1.30 | Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidation. ( Arnold, LA; Camp, DM; Hyland, K; Juneau, PL; LeWitt, PA; Loeffler, DA, 1998) |
| "Pretreatment with riluzole (8 mg kg-1, i." | 1.29 | Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo. ( Boireau, A; Doble, A; Dubédat, P; Meunier, M; Miquet, JM, 1994) |
| "The behavioural, biochemical and morphological effects of a chronic administration of low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were studied in the common marmoset." | 1.29 | Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. ( Albanese, A; Colosimo, C; Granata, R; Gregori, B; Piccardi, MP; Tonali, P, 1993) |
| "Treatment with bromocriptine (5 mg/kg) relieved the parkinsonian symptoms, but the efficacy of this treatment appeared to decrease slightly with time." | 1.28 | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393. ( Bédard, PJ; Di Paolo, T; Rouillard, C, 1990) |
| " Chronic administration of L-deprenyl (0." | 1.28 | Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice. ( Hashim, A; Lajtha, A; Sershen, H; Wiener, HL, 1989) |
| "In experimental Parkinson's disease, we studied the effects of chronic administration (30 days), withdrawal, and reinstitution of bromocriptine." | 1.27 | Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats. ( Baden, DR; Kenny, AM; Murrin, LC; Pfeiffer, RF; Schneider, MB, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (23.21) | 18.7374 |
| 1990's | 46 (41.07) | 18.2507 |
| 2000's | 29 (25.89) | 29.6817 |
| 2010's | 9 (8.04) | 24.3611 |
| 2020's | 2 (1.79) | 2.80 |
| Authors | Studies |
|---|---|
| Antunes, MS | 2 |
| Ladd, FVL | 1 |
| Ladd, AABL | 1 |
| Moreira, AL | 1 |
| Boeira, SP | 3 |
| Cattelan Souza, L | 2 |
| Sun, J | 1 |
| He, C | 1 |
| Yan, QX | 1 |
| Wang, HD | 1 |
| Li, KX | 1 |
| Sun, X | 1 |
| Feng, Y | 1 |
| Zha, RR | 1 |
| Cui, CP | 1 |
| Xiong, X | 1 |
| Gao, S | 1 |
| Wang, X | 1 |
| Yin, RX | 1 |
| Qiao, GF | 1 |
| Li, BY | 1 |
| Madiha, S | 1 |
| Tabassum, S | 1 |
| Batool, Z | 1 |
| Liaquat, L | 1 |
| Sadir, S | 1 |
| Shahzad, S | 1 |
| Perveen, T | 1 |
| Haider, S | 1 |
| Goes, ATR | 1 |
| Jesse, CR | 2 |
| Lobo Ladd, FV | 2 |
| Lobo Ladd, AAB | 2 |
| Luchese, C | 1 |
| Paroul, N | 1 |
| Del Fabbro, L | 1 |
| Rossito Goes, A | 1 |
| de Gomes, MG | 1 |
| Nunes Arantes, RV | 1 |
| Reis Simionato, A | 1 |
| Oliveira, MS | 1 |
| Furian, AF | 1 |
| Rekha, KR | 1 |
| Selvakumar, GP | 1 |
| Santha, K | 1 |
| Inmozhi Sivakamasundari, R | 1 |
| Yu, LH | 1 |
| Wei, HL | 1 |
| Bao, XQ | 1 |
| Zhang, D | 1 |
| Sun, H | 1 |
| Goldstein, DS | 1 |
| Sullivan, P | 1 |
| Cooney, A | 1 |
| Jinsmaa, Y | 1 |
| Kopin, IJ | 1 |
| Sharabi, Y | 1 |
| Moraes, LS | 1 |
| Rohor, BZ | 1 |
| Areal, LB | 1 |
| Pereira, EV | 1 |
| Santos, AM | 1 |
| Facundo, VA | 1 |
| Santos, AR | 1 |
| Pires, RG | 1 |
| Martins-Silva, C | 1 |
| Joniec, I | 1 |
| Ciesielska, A | 1 |
| Kurkowska-Jastrzebska, I | 1 |
| Przybylkowski, A | 1 |
| Czlonkowska, A | 1 |
| Czlonkowski, A | 1 |
| Thakur, P | 1 |
| Nehru, B | 1 |
| Lin, L | 1 |
| Meng, T | 1 |
| Liu, T | 1 |
| Zheng, Z | 1 |
| McCormack, AL | 1 |
| Thiruchelvam, M | 2 |
| Manning-Bog, AB | 1 |
| Thiffault, C | 1 |
| Langston, JW | 2 |
| Cory-Slechta, DA | 2 |
| Di Monte, DA | 2 |
| Choi, JY | 1 |
| Park, CS | 1 |
| Kim, DJ | 1 |
| Cho, MH | 1 |
| Jin, BK | 1 |
| Pie, JE | 1 |
| Chung, WG | 1 |
| Kaur, D | 1 |
| Yantiri, F | 1 |
| Rajagopalan, S | 1 |
| Kumar, J | 1 |
| Mo, JQ | 1 |
| Boonplueang, R | 1 |
| Viswanath, V | 1 |
| Jacobs, R | 1 |
| Yang, L | 1 |
| Beal, MF | 3 |
| DiMonte, D | 1 |
| Volitaskis, I | 1 |
| Ellerby, L | 1 |
| Cherny, RA | 1 |
| Bush, AI | 1 |
| Andersen, JK | 2 |
| Cohen, AD | 2 |
| Tillerson, JL | 2 |
| Smith, AD | 1 |
| Schallert, T | 3 |
| Zigmond, MJ | 2 |
| Wang, W | 1 |
| Zhao, DZ | 1 |
| Sun, XF | 1 |
| Gu, SD | 1 |
| Zhuo, M | 1 |
| Xu, DH | 1 |
| Cao, L | 1 |
| Xu, LF | 1 |
| Yu, FR | 1 |
| Zheng, ZC | 1 |
| Liu, XY | 1 |
| Ahmad, AS | 1 |
| Ansari, MA | 1 |
| Ahmad, M | 1 |
| Saleem, S | 1 |
| Yousuf, S | 1 |
| Hoda, MN | 1 |
| Islam, F | 1 |
| Taylor, JL | 1 |
| Bishop, C | 1 |
| Walker, PD | 1 |
| Li, X | 1 |
| Matsumoto, K | 1 |
| Murakami, Y | 1 |
| Tezuka, Y | 1 |
| Wu, Y | 1 |
| Kadota, S | 1 |
| Chaturvedi, RK | 1 |
| Shukla, S | 1 |
| Seth, K | 1 |
| Agrawal, AK | 1 |
| Cannon, JR | 1 |
| Keep, RF | 1 |
| Hua, Y | 1 |
| Richardson, RJ | 1 |
| Xi, G | 2 |
| Rojo, AI | 1 |
| Cavada, C | 1 |
| de Sagarra, MR | 1 |
| Cuadrado, A | 1 |
| Pérez, V | 1 |
| Sosti, V | 1 |
| Rubio, A | 1 |
| Barbanoj, M | 1 |
| Rodríguez-Alvarez, J | 1 |
| Kulisevsky, J | 1 |
| Jenner, P | 4 |
| Rupniak, NM | 1 |
| Rose, S | 4 |
| Kelly, E | 2 |
| Kilpatrick, G | 2 |
| Lees, A | 1 |
| Marsden, CD | 5 |
| Fornaguera, J | 1 |
| Schwarting, RK | 1 |
| Boix, F | 1 |
| Huston, JP | 1 |
| Wesemann, W | 2 |
| Grote, C | 2 |
| Clement, HW | 2 |
| Block, F | 1 |
| Sontag, KH | 2 |
| Boireau, A | 3 |
| Dubédat, P | 2 |
| Bordier, F | 1 |
| Peny, C | 1 |
| Miquet, JM | 2 |
| Durand, G | 1 |
| Meunier, M | 2 |
| Doble, A | 2 |
| Nomoto, M | 3 |
| Irifune, M | 1 |
| Fukuzaki, K | 1 |
| Fukuda, T | 1 |
| Sarre, S | 1 |
| De Klippel, N | 1 |
| Herregodts, P | 1 |
| Ebinger, G | 1 |
| Michotte, Y | 1 |
| Pérez-Otaño, I | 1 |
| Oset, C | 1 |
| Luquin, MR | 1 |
| Herrero, MT | 1 |
| Obeso, JA | 1 |
| Del Río, J | 1 |
| Albanese, A | 2 |
| Granata, R | 1 |
| Gregori, B | 1 |
| Piccardi, MP | 1 |
| Colosimo, C | 1 |
| Tonali, P | 1 |
| Schneider, JS | 5 |
| DiStefano, L | 3 |
| Gomez-Mancilla, B | 1 |
| Boucher, R | 3 |
| Gagnon, C | 1 |
| Di Paolo, T | 4 |
| Markstein, R | 1 |
| Bédard, PJ | 3 |
| Hantraye, P | 1 |
| Brouillet, E | 1 |
| Ferrante, R | 1 |
| Palfi, S | 1 |
| Dolan, R | 1 |
| Matthews, RT | 1 |
| Solbach, M | 1 |
| Nafe, R | 1 |
| Riederer, P | 3 |
| Jellinger, K | 2 |
| Mennel, HD | 1 |
| Cintra, A | 1 |
| Andbjer, B | 1 |
| Finnman, UB | 1 |
| Hagman, M | 1 |
| Agnati, LF | 1 |
| Höglund, G | 1 |
| Fuxe, K | 1 |
| Royland, JE | 1 |
| Jakowec, MW | 1 |
| Hattori, S | 1 |
| Hashitani, T | 2 |
| Matsui, N | 1 |
| Nishino, H | 2 |
| Gerlach, M | 1 |
| Gsell, W | 1 |
| Kornhuber, J | 1 |
| Krieger, V | 1 |
| Pantucek, F | 1 |
| Vock, R | 1 |
| Sullivan, AM | 1 |
| Opacka-Juffry, J | 1 |
| Hötten, G | 1 |
| Pohl, J | 1 |
| Blunt, SB | 1 |
| Zhu, W | 1 |
| Ju, J | 1 |
| Matsubara, K | 1 |
| Gonda, T | 1 |
| Sawada, H | 1 |
| Uezono, T | 1 |
| Kobayashi, Y | 1 |
| Kawamura, T | 1 |
| Ohtaki, K | 1 |
| Kimura, K | 1 |
| Akaike, A | 1 |
| Naoi, M | 1 |
| Maruyama, W | 1 |
| Kasamatsu, T | 1 |
| Dostert, P | 1 |
| Mizukawa, K | 1 |
| Kumazaki, M | 1 |
| Horger, BA | 1 |
| Nishimura, MC | 1 |
| Armanini, MP | 1 |
| Wang, LC | 1 |
| Poulsen, KT | 1 |
| Rosenblad, C | 1 |
| Kirik, D | 1 |
| Moffat, B | 1 |
| Simmons, L | 1 |
| Johnson, E | 1 |
| Milbrandt, J | 1 |
| Rosenthal, A | 1 |
| Bjorklund, A | 1 |
| Vandlen, RA | 1 |
| Hynes, MA | 1 |
| Phillips, HS | 1 |
| Teicher, MH | 1 |
| Andersen, SL | 1 |
| Campbell, A | 1 |
| Gelbard, HA | 1 |
| Baldessarini, RJ | 1 |
| Di Rocco, A | 1 |
| Brannan, T | 1 |
| Prikhojan, A | 1 |
| Yahr, MD | 1 |
| Robles, M | 1 |
| Choi, BH | 1 |
| Han, B | 1 |
| Santa Cruz, K | 1 |
| Kim, RC | 1 |
| Cheng, FC | 1 |
| Ni, DR | 1 |
| Wu, MC | 1 |
| Kuo, JS | 1 |
| Chia, LG | 1 |
| Blanchet, PJ | 1 |
| Konitsiotis, S | 1 |
| Hyland, K | 2 |
| Arnold, LA | 2 |
| Pettigrew, KD | 1 |
| Chase, TN | 1 |
| Loeffler, DA | 1 |
| LeWitt, PA | 1 |
| Juneau, PL | 1 |
| Camp, DM | 1 |
| Dethy, S | 1 |
| Laute, MA | 1 |
| Damhaut, P | 1 |
| Goldman, S | 1 |
| Carlson, JD | 1 |
| Pearlstein, RD | 1 |
| Buchholz, J | 1 |
| Iacono, RP | 1 |
| Maeda, G | 1 |
| Kucherianu, VG | 1 |
| Kryzhanovskiĭ, GN | 1 |
| Kudrin, VS | 1 |
| Iurasov, VV | 1 |
| Nikushkin, EV | 1 |
| Zhigal'tsev, IV | 1 |
| Lindner, MD | 1 |
| Cain, CK | 1 |
| Plone, MA | 1 |
| Frydel, BR | 1 |
| Blaney, TJ | 1 |
| Emerich, DF | 1 |
| Hoane, MR | 1 |
| Fillebeen, C | 1 |
| Mitchell, V | 1 |
| Dexter, D | 1 |
| Benaissa, M | 1 |
| Beauvillain, J | 1 |
| Spik, G | 1 |
| Pierce, A | 1 |
| Ferger, B | 1 |
| Teismann, P | 1 |
| Earl, CD | 1 |
| Kuschinsky, K | 1 |
| Oertel, WH | 1 |
| Klivenyi, P | 1 |
| Andreassen, OA | 1 |
| Ferrante, RJ | 1 |
| Dedeoglu, A | 1 |
| Mueller, G | 1 |
| Lancelot, E | 1 |
| Bogdanov, M | 1 |
| Jiang, D | 1 |
| Ueda, S | 1 |
| Aikawa, M | 1 |
| Ishizuya-Oka, A | 1 |
| Yamaoka, S | 1 |
| Koibuchi, N | 1 |
| Yoshimoto, K | 1 |
| Ben, V | 1 |
| Blin, O | 1 |
| Bruguerolle, B | 1 |
| Disshon, KA | 1 |
| Dluzen, DE | 1 |
| Bezard, E | 2 |
| Jaber, M | 1 |
| Gonon, F | 1 |
| Bloch, B | 1 |
| Gross, CE | 2 |
| Nash, JE | 1 |
| Brotchie, JM | 2 |
| Richfield, EK | 1 |
| Baggs, RB | 1 |
| Tank, AW | 1 |
| Costa, G | 1 |
| Abin-Carriquiry, JA | 1 |
| Dajas, F | 1 |
| Philhower, J | 1 |
| Miller, GW | 1 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
| Belforte, JE | 1 |
| Magariños-Azcone, C | 1 |
| Armando, I | 1 |
| Buño, W | 1 |
| Pazo, JH | 1 |
| Dovero, S | 1 |
| Prunier, C | 1 |
| Ravenscroft, P | 1 |
| Chalon, S | 1 |
| Guilloteau, D | 1 |
| Crossman, AR | 1 |
| Bioulac, B | 1 |
| Kitazawa, M | 1 |
| Anantharam, V | 1 |
| Kanthasamy, AG | 1 |
| Barthwal, MK | 1 |
| Srivastava, N | 1 |
| Dikshit, M | 1 |
| Leret, ML | 1 |
| San Millán, JA | 1 |
| Fabre, E | 1 |
| Gredilla, R | 1 |
| Barja, G | 1 |
| Fredduzzi, S | 1 |
| Moratalla, R | 1 |
| Monopoli, A | 1 |
| Cuellar, B | 1 |
| Xu, K | 1 |
| Ongini, E | 1 |
| Impagnatiello, F | 1 |
| Schwarzschild, MA | 1 |
| Chen, JF | 1 |
| Hoehn, MM | 1 |
| Crowley, TJ | 1 |
| Rutledge, CO | 1 |
| Pope, A | 1 |
| Simpson, K | 1 |
| Taggart, J | 1 |
| Smith, MG | 1 |
| Mierau, J | 1 |
| Schingnitz, G | 1 |
| Lisovoski, F | 1 |
| Haby, C | 1 |
| Borrelli, E | 1 |
| Schleef, C | 1 |
| Revel, MO | 1 |
| Hindelang, C | 1 |
| Zwiller, J | 1 |
| Skirboll, S | 1 |
| Wang, J | 1 |
| Mefford, I | 1 |
| Hsiao, J | 1 |
| Bankiewicz, KS | 1 |
| Rausch, WD | 1 |
| Schallauer, E | 1 |
| Chan, WW | 1 |
| Weiser, M | 1 |
| Jolicoeur, FB | 1 |
| Rivest, R | 1 |
| St-Pierre, S | 1 |
| Drumheller, A | 1 |
| Fazzini, E | 1 |
| Durso, R | 1 |
| Davoudi, H | 1 |
| Szabo, GK | 1 |
| Albert, ML | 1 |
| Rouillard, C | 1 |
| Bradbury, AJ | 1 |
| Costall, B | 1 |
| Jenner, PG | 1 |
| Kelly, ME | 1 |
| Naylor, RJ | 1 |
| Bédard, P | 1 |
| Daigle, M | 1 |
| Johannessen, JN | 1 |
| Savitt, JM | 1 |
| Markey, CJ | 1 |
| Bacon, JP | 1 |
| Weisz, A | 1 |
| Hanselman, DS | 1 |
| Markey, SP | 1 |
| Teelken, AW | 1 |
| van den Berg, GA | 1 |
| Muskiet, FA | 1 |
| Staal-Schreinemachers, AL | 1 |
| Wolthers, BG | 1 |
| Lakke, JP | 1 |
| Wiener, HL | 1 |
| Hashim, A | 1 |
| Lajtha, A | 1 |
| Sershen, H | 1 |
| Ueki, A | 1 |
| Chong, PN | 1 |
| Chivers, JK | 1 |
| Jackson, EA | 1 |
| Gibb, WR | 1 |
| Hadjiconstantinou, M | 1 |
| Mariani, AP | 1 |
| Neff, NH | 1 |
| Russ, H | 1 |
| Henning, K | 1 |
| Eckhardt, H | 1 |
| Przuntek, H | 1 |
| Collins, MA | 2 |
| Neafsey, EJ | 2 |
| Camps, M | 1 |
| Ambrosio, S | 1 |
| Ballarin, M | 1 |
| Reiriz, J | 1 |
| Blesa, R | 1 |
| Mahy, N | 1 |
| Kenny, AM | 1 |
| Schneider, MB | 1 |
| Baden, DR | 1 |
| Pfeiffer, RF | 1 |
| Murrin, LC | 1 |
| Perry, TL | 2 |
| Jones, K | 2 |
| Hansen, S | 2 |
| Wall, RA | 1 |
| Saitoh, T | 1 |
| Hood, TW | 1 |
| Domino, EF | 1 |
| Greenberg, HS | 1 |
| Ghilardi, MF | 1 |
| Chung, E | 1 |
| Bodis-Wollner, I | 1 |
| Dvorzniak, M | 1 |
| Glover, A | 1 |
| Onofrj, M | 1 |
| Falardeau, P | 1 |
| Bouchard, S | 1 |
| Schultz, W | 1 |
| Scarnati, E | 1 |
| Sundström, E | 1 |
| Tsutsumi, T | 1 |
| Jonsson, G | 1 |
| Zimmerman, DM | 1 |
| Cantrell, BE | 1 |
| Reel, JK | 1 |
| Hemrick-Luecke, SK | 1 |
| Fuller, RW | 1 |
| Eidelberg, E | 1 |
| Brooks, BA | 1 |
| Morgan, WW | 1 |
| Walden, JG | 1 |
| Kokemoor, RH | 1 |
| Cheng, BY | 1 |
| Hurley-Gius, K | 1 |
| Ung-Chhun, NA | 1 |
| Pronger, DA | 1 |
| Christensen, MA | 1 |
| Hurley-Gius, D | 1 |
| Heikkila, RE | 1 |
| Sonsalla, PK | 1 |
112 other studies available for 3,4-dihydroxyphenylacetic acid and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Hesperidin protects against behavioral alterations and loss of dopaminergic neurons in 6-OHDA-lesioned mice: the role of mitochondrial dysfunction and apoptosis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apoptosis; Behavior, Animal; Discrimination Learning; Dopam | 2021 |
Parkinson-like early autonomic dysfunction induced by vagal application of DOPAL in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Autonomic Nervous System Diseases; Baroref | 2021 |
Assessment of gait dynamics in rotenone-induced rat model of Parkinson's disease by footprint method.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; | 2017 |
Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Flavonoids; Gene Expression Regulatio | 2018 |
Chrysin protects against behavioral, cognitive and neurochemical alterations in a 6-hydroxydopamine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Cognition; Dopamine; Female; Flavonoids; Homovanilli | 2019 |
Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acyclic Monoterpenes; | 2013 |
[Therapeutic effect of a natural squamosamide derivative FLZ on Parkinson's disease model mice induced by LPS plus MPTP].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acrylamides; Animals; | 2013 |
Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Brain Neoplasms; Dopamine; Electron | 2015 |
Medicinal plant Combretum leprosum mart ameliorates motor, biochemical and molecular alterations in a Parkinson's disease model induced by MPTP.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Combretum; Dopamine; Gene Expression Regulation; Homovanill | 2016 |
Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Analysis of Variance; Animals; Blotting, Western; Chrom | 2009 |
Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflammatory Agents; Antioxidants; Brain; Catalase; Cy | 2013 |
Increased melatonin may play dual roles in the striata of a 6-hydroxydopamine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Data | 2013 |
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Environm | 2002 |
Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Wes | 2002 |
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Wes | 2003 |
Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Casts, Surgical; Corpus Stri | 2003 |
[The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Dopamine; Drug Combinations; Drug Syner | 2002 |
Long term gene therapy of Parkinson's disease using immortalized rat glial cell line with tyrosine hydroxylase gene.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cell Line, Transformed; Corpus Striatum; | 2003 |
Neuroprotection by crocetin in a hemi-parkinsonian rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Carotenoids; Catala | 2005 |
Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Corpu | 2005 |
Neuroprotective effects of Polygonum multiflorum on nigrostriatal dopaminergic degeneration induced by paraquat and maneb in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; | 2005 |
Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Transplantation; Corpus Striatum; Dopamine; Embryo, Ma | 2006 |
Protease-activated receptor-1 mediates protection elicited by thrombin preconditioning in a rat 6-hydroxydopamine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Biotransformation; Catecholamines; Foreli | 2006 |
Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Inhala | 2007 |
Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antip | 2007 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Callitrichina | 1984 |
Behavioral indices of moderate nigro-striatal 6-hydroxydopamine lesion: a preclinical Parkinson's model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Functi | 1993 |
Functional studies on monoaminergic transmitter release in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; A | 1993 |
Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopami | 1994 |
Effects of bifemelane on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressiv | 1994 |
Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Exc | 1994 |
Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Biotransformation; Corpus Striatum; Denervatio | 1994 |
MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1994 |
Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1993 |
LIGA 20 increases striatal dopamine levels in aged MPTP-treated mice refractory to GM1 ganglioside treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Drug Resis | 1993 |
Oral administration of semisynthetic sphingolipids promotes recovery of striatal dopamine concentrations in a murine model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; | 1994 |
Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopam | 1993 |
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Model | 1996 |
Effect of lazaroid U-74389G on iron-induced reduction of striatal dopamine metabolism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Corpus Striatum; Dopamine; Injections; Iron; | 1995 |
Subacute toluene exposure increases DA dysfunction in the 6-OH dopamine lesioned nigrostriatal dopaminergic system of the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Drug Administration Schedule; Dr | 1996 |
Role of nitric oxide in methamphetamine neurotoxicity: protection by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Temperature; Dopamine Agents; Enzyme Inhibitors; Homov | 1996 |
Dynamic regulation of striatal dopaminergic grafts during locomotor activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Transplantation; Corpus Striatum; Dopamine; Extracellu | 1996 |
A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Basal Ganglia; Biomarkers; Cerebral Cortex; | 1996 |
Preservation of autoreceptor-mediated increases in dopamine synthesis in aged mice with experimentally-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Aromat | 1997 |
Growth/differentiation factor 5 protects nigrostriatal dopaminergic neurones in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bone Morphogenetic Proteins; Corpus Striatum; Dopamine; Gro | 1997 |
[Effect of acupuncture and Chinese medicine treatment on brain dopamine level of MPTP-lesioned C57BL mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acupuncture Therapy; A | 1996 |
Endogenously occurring beta-carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Brain; Carbolines; Cells, Cultured; Do | 1998 |
Oxidation of N-methyl(R)salsolinol: involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Corpus Striatum; Cycloheximide; Disease Model | 1998 |
Dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Brain Tissue Transplantation; Carrier Prot | 1998 |
Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Survival; Cells, Cultured; Corpus Striatum; Disease Mo | 1998 |
Progressive accumbens degeneration after neonatal striatal 6-hydroxydopamine in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Caudate Nucleus; Chromatography, High Pre | 1998 |
Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism.
Topics: 1-Naphthylamine; 3,4-Dihydroxyphenylacetic Acid; Aged; Animals; Antidepressive Agents, Second-Genera | 1998 |
Repin-induced neurotoxicity in rodents.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cytotoxins; Dopamine; Encephalomalacia; Glutathione; Immuno | 1998 |
Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; | 1998 |
Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; B | 1998 |
Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Cerebellum; Corpus Striatum; Dopamine; Dopamine Agen | 1998 |
Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Ago | 1999 |
Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's model rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antimetabolites; Basal Ganglia Diseases; Cerebral Cortex; D | 1999 |
[Effect of acidic fibroblast growth factor on experimental parkinsonism and levels of dopamine and its metabolites in the striatum of mice of various ages].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Intran | 1999 |
Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Brain Mapping; Corpus Striatum; Dementia; Dopa | 1999 |
Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catalase; Cor | 1999 |
Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflamma | 1999 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
Age-related dopamine deficiency in the mesostriatal dopamine system of zitter mutant rats: regional fiber vulnerability in the striatum and the olfactory tubercle.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Antibodies; Disease Models, Animal; Dopamine; Free R | 2000 |
Time-dependent striatal dopamine depletion after injection of 6-hydroxydopamine in the rat. Comparison of single bilateral and double bilateral lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dise | 1999 |
Estrogen reduces acute striatal dopamine responses in vivo to the neurotoxin MPP+ in female, but not male rats.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Est | 2000 |
Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Proteins; Cell Count; Corpus Striatum; Disease Mode | 2000 |
A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Corpus Striatum; Cyclic AMP; Disease | 2000 |
The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Weight; Carrier Proteins; Cell Count; Corpus Striatum; | 2000 |
Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chlorisondamine; Corpus Striatum; Disease Models, Animal; D | 2001 |
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Body Temperature; Casts, Sur | 2001 |
Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dru | 2001 |
Pharmacological involvement of the calcium channel blocker flunarizine in dopamine transmission at the striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Calcium Channel Blockers; Calcium Channels, L- | 2001 |
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiograp | 2001 |
Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptopic cell death in dopaminergic cells.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apoptosis; Cell Survival; Chromatography, High Pressure Liq | 2001 |
Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; | 2001 |
Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2002 |
Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adaptation, Physiological; Animals; Autoradiography; Behavior, Anima | 2002 |
The Parkinsonian syndrome and its dopamine correlates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dopamine; Extrapyramidal Tracts; Female; Homovanillic A | 1977 |
Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1992 |
Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzothiazoles; Corpus Striatum; Dihydroxyphenylalanine; Do | 1992 |
Induction of D2 dopamine receptor mRNA synthesis in a 6-hydroxydopamine parkinsonian rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Blotting, Northern; Corpus Striatum; Dopamine; | 1992 |
MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cats; Caudate Nucleus; Dopamine; Female; | 1992 |
In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamine | 1990 |
Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amantadine; Animals; C | 1990 |
Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Ca | 1991 |
GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1990 |
Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1990 |
The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Female; Homov | 1985 |
Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1986 |
The development of amine substituted analogues of MPTP as unique tools for the study of MPTP toxicity and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amines; Animals; Brain | 1987 |
Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Catecholamines; Dopamine; Droxidopa; Female; Homovanillic Acid | 1989 |
Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1989 |
Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Callitrichina | 1989 |
Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiograp | 1989 |
Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allylamine; Animals; B | 1989 |
GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1989 |
The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucle | 1985 |
Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirg | 1985 |
Dopamine D1 and D2 receptors visualized in MPTP treated C57 mice by in vitro autoradiography: lack of evidence of receptor modifications in parkinsonian mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Benzazepines; Brain; Dopamine; Homovanilli | 1989 |
Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Binding Sites; Bromocriptine; Dopamine; D | 1986 |
2-Phenylpyridine and 3-phenylpyridine, constituents of tea, are unlikely to cause idiopathic Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Female; Homovanillic Acid; Mice; | 1988 |
Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Clomipramine; | 1988 |
Possible treatment of Parkinson's disease with intrathecal medication in the MPTP model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Homovanillic | 1988 |
Systemic 1-methyl,4-phenyl,1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatograph | 1988 |
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1988 |
The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia | 1986 |
Characterization of the neurotoxic potential of m-methoxy-MPTP and the use of its N-ethyl analogue as a means of avoiding exposure to a possible Parkinsonism-causing agent.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Corpus | 1986 |
Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 1986 |
Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirg | 1987 |
Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1987 |
The use of the MPTP-treated mouse as an animal model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1987 |